Recruiting
Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan…
ClinicalTrials.gov IDNCT05745961
PhaseNot Applicable
Enrollment6
SponsorImperial College London
Age25 Years
SexALL
Conditions studied
Pulmonary Arterial Hypertension, Healthy
About this study
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.
Interventions
- Radiation: TSPO PET scan (11C-PBR28) — PET scan
Primary outcomes
- The specific and non-specific fractions of the [11C]PBR28 signal in the lungs of healthy individuals and PAH patients. (2 years)
Eligibility information
Inclusion Criteria:
Able to provide written informed consent prior to any study mandated procedures.
Able to lie comfortably on back for up to 90 minutes at a time.
Fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if they are taking a highly effective method of contraception other than the oral contraceptive pill until the end of relevant systemic exposure.
Male participants who are fertile are eligible to participate if they are willing to comply with the contraceptive requirements
Exclusion Criteria:
Unable to provide informed consent and/or are non-fluent speakers of the English language
TT Genotype at the rs6971 locus
Clinically-significant renal disease (confirmed by creatinine clearance \<30 ml/min per 1.73m2)
Clinically-significant liver disease (confirmed by serum transaminases \>2 times than upper normal limit)
Anaemia confirmed by haemoglobin concentration \<10 g/dl
Sickle cell disease or thalassaemia
History of uncontrolled systemic hypertension
Acute infection (including eye, dental, and skin infections)
Chronic inflammatory disease including HIV, and Hepatitis B
Women of childbearing potential who are pregnant or breastfeeding
Patients who have received an Investigational Medicinal Product (IMP) within 5 half-lives of the last dose of the IMP or 1 month (which ever is greater) before the baseline visit
Participation in a research study involving significant ionisation radiation within the last 3 years
Significant radiation exposure other than dental X-rays in last 1 year
Positive Allen's test.
\-
Study locations
- Imperial Clinical Research Facility, London, NW3 2LE United Kingdom
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.